Growth Metrics

Vanda Pharmaceuticals (VNDA) Cash from Investing Activities (2016 - 2025)

Vanda Pharmaceuticals' Cash from Investing Activities history spans 16 years, with the latest figure at $44.9 million for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities rose 1023.62% to $44.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $94.9 million, a 644.23% increase, with the full-year FY2025 number at $94.9 million, up 644.23% from a year prior.
  • Cash from Investing Activities hit $44.9 million in Q4 2025 for Vanda Pharmaceuticals, up from $21.4 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for VNDA hit a ceiling of $187.3 million in Q1 2023 and a floor of -$190.9 million in Q2 2023.
  • Historically, Cash from Investing Activities has averaged $1.9 million across 5 years, with a median of -$7.3 million in 2021.
  • Biggest five-year swings in Cash from Investing Activities: plummeted 1351.13% in 2021 and later skyrocketed 15204.23% in 2022.
  • Tracing VNDA's Cash from Investing Activities over 5 years: stood at -$26.0 million in 2021, then soared by 390.13% to $75.4 million in 2022, then tumbled by 158.05% to -$43.8 million in 2023, then skyrocketed by 109.12% to $4.0 million in 2024, then surged by 1023.62% to $44.9 million in 2025.
  • Business Quant data shows Cash from Investing Activities for VNDA at $44.9 million in Q4 2025, $21.4 million in Q3 2025, and -$15.3 million in Q2 2025.